Merck Fosamax patent upheld
Executive Summary
Merck's Fosamax (alendronate) will not face generic competition until at least August 2007, following a decision by Wilmington, Del., federal court to uphold a method of use patent for the osteoporosis drug Nov. 4. Teva intends to appeal the decision...
You may also be interested in...
Merck Fosamax once-weekly patent upheld
Merck Fosamax once-weekly dose will not face generic competition until 2019, under a ruling by the Wilmington, Del. federal court to uphold a method of use patent (no. 5,994,329) for the 35 mg and 70 mg strengths of the osteoporosis agent. Teva plans to appeal the decision; the company is also awaiting a ruling on its appeal of the same court's decision to uphold Merck's method of use patent covering the Fosamax (alendronate) once-daily products (1"The Pink Sheet" Nov. 11, 2002, In Brief)...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.